Abstract:Background: Epidermal growth factor receptor (EGFR) is an attractive therapeutic target for a number of human tumors including non-small cell lung cancer (NSCLC). Most patients with NSCLC and somatic mutations have shown a dramatic initial clinical response to reversible EGFR inhibitors. The clinical efficacy of reversible inhibitors is, however, ultimately limited due to the emergence of drug resistance, which is usually conferred by the EGFR T790M mutation. Importantly, irreversible, synthetic small molecule inhibitors are currently evaluated and some of them have been shown to overcome the acquired resistance that is oftentimes observed in these patients. Thus far, irreversible EGFR inhibitors as a drug class have not received regulatory approval due in part to their poor effectiveness at clinically achievable concentrations. Therefore, there is an urgent need to discover and develop novel, potent irreversible inhibitors against the EGFR T790M mutation. Material and methods: In the following study, we report a novel "hybrid strategy" to identify irreversible EGFR inhibitors with active scaffolds starting with the identification and extraction of a common chemical reactive feature and a pharmacophore feature. The chemical reactive feature was elucidated by investigating 138 currently known irreversible inhibitors at B3LYP/6-31G(d) level using the density function theory method. The pharmacophore feature was extracted from the same inhibitors using pharmacophore modeling. Based on these unique features, two constraints were set while calibrating the protocols of in silico screening. Compounds bearing these specific features were obtained from the National Cancer Institute diversity database to form our subsequent library. Finally, a structure based virtual screening against the library was conducted using standard protocols validated in our lab. Results: Twenty-eight candidate compounds that demonstrated antitumor activity and that had novel scaffolds different from commonly known quinazoline/quinoline analogs were obtained. The interaction modes between three representative candidates and our model system are similar to that between the model system and the reference compound T-001, which has previously been reported to be one of the most potent of the 138 irreversible inhibitors. Conclusion: The hybrid strategy starting with the extraction of common features is an effective approach to design potential irreversible inhibitors with novel scaffolds and therefore to obtain lead molecules in the selection process. These candidates possessing unique scaffolds have a strong likelihood to act as further starting points in the preclinical development of potent irreversible T790M EGFR inhibitors.

Effective Reaction-Based De Novo Strategy for Kinase Targets: A Case Study on MERTK Inhibitors

Kinase Inhibitor Data Modeling and De Novo Inhibitor Design with Fragment Approaches.

Molecular Modelling Studies on Pyrazole Derivatives for the Design of Potent Rearranged during Transfection Kinase Inhibitors

Design of New Second‐Generation TRK Inhibitors Targeting Tropomyosin Receptor Kinases by Using Molecular Docking, Molecular Dynamics Simulations and ADMET Properties

De Novo Design of VEGFR-2 Tyrosine Kinase Inhibitors Based on a Linked-Fragment Approach

The Discovery of Novel Vascular Endothelial Growth Factor Receptor Tyrosine Kinases Inhibitors: Pharmacophore Modeling, Virtual Screening and Docking Studies

De novo design of N -(pyridin-4-ylmethyl)aniline derivatives as KDR inhibitors: 3D-QSAR, molecular fragment replacement, protein-ligand interaction fingerprint, and ADMET prediction

Design, Synthesis, and Biochemical Evaluation of Novel MLK3 Inhibitors: A Target Hopping Example

Design, Synthesis and Evaluation of Novel Phorbazole C Derivatives as MNK Inhibitors through Virtual High-Throughput Screening

In Silico Exploration of Novel EGFR Kinase Mutant-Selective Inhibitors Using a Hybrid Computational Approach

Design, synthesis and biological evaluation of MNK-PROTACs

In silico identification of EGFR-T790M inhibitors with novel scaffolds: start with extraction of common features.

Discovery of Novel Inhibitors for C-Met by Virtual Screening and Pharmacophore Analysis

Accelerating De Novo Drug Design against Novel Proteins Using Deep Learning

Discovery, Optimization and Biological Evaluation for Novel C-Met Kinase Inhibitors

Design and discovery of monopolar spindle kinase 1 (MPS1/TTK) inhibitors by computational approaches

In Silico Design of New B-Raf Kinase Type-II Inhibitors Through Combined Molecular Modeling Studies

Discovery of Novel Macrocyclic MERTK/AXL Dual Inhibitors

Structure-Based de Novo Molecular Generator Combined with Artificial Intelligence and Docking Simulations

Discovering Potent Inhibitors Against C-Met Kinase: Molecular Design, Organic Synthesis and Bioassay

Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations